Preoperative hydronephrosis: Independent predictor for changes in renal function following nephroureterectomy

Katsura Hoshino, Eiji Kikuchi, Nobuyuki Tanaka, Hirotaka Akita, Yujiro Ito, Akira Miyajima, Masahiro Jinzaki, Mototsugu Oya

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Partial or complete urinary obstruction caused by a tumor itself may affect renal function and the eligibility for perioperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma. We investigated whether the status of preoperative hydronephrosis provides additional predictive information concerning changes in perioperative renal function. Methods: A total of 155 patients who underwent nephroureterectomy for upper tract urothelial carcinoma from 1997 to 2010 were identified. The association between preoperative parameters including the grade of hydronephrosis and perioperative renal function was analyzed. Results: Hydronephrosis was observed in 104 patients. The grade of hydronephrosis was 1, 2, 3 and 4 in 6 (3.9%), 25 (16.1%), 42 (27.1%) and 31 (20.0%) cases. Using a defined cut-off creatinine clearance value of ≥50 ml/min indicating eligibility for cisplatin-based chemotherapy, only 94 patients (60.6%) were eligible in the neoadjuvant setting. Of these 94 patients, 30 (31.9%) were judged to be ineligible in the adjuvant setting. Multivariate analysis demonstrated that patient age ≥70 years [P < 0.001, hazard ratio (HR) 27.9] and the absence of a higher grade hydronephrosis (P = 0.013, HR 7.40) were independent risk factors for predicting patients ineligible to receive adjuvant cisplatin-based chemotherapy. The proportion of patients ineligible to receive cisplatin-based chemotherapy changed from 40.9 to 88.6% following nephroureterectomy in patients aged ≥70 years and those with no or a lower grade hydronephrosis. Conclusions: The status of hydronephrosis is an independent predictor of eligibility to receive adjuvant cisplatin-based chemotherapy. The information on preoperative hydronephrosis and patient age may assist in part of the decision-making when considering neoadjuvant cisplatin-based chemotherapy.

Original languageEnglish
Article numberhyr199
Pages (from-to)202-207
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume42
Issue number3
DOIs
Publication statusPublished - 2012 Mar

Fingerprint

Hydronephrosis
Kidney
Cisplatin
Drug Therapy
Carcinoma
Creatinine
Decision Making
Multivariate Analysis

Keywords

  • Age
  • Hydronephrosis
  • Nephroureterectomy
  • Renal function
  • Upper tract urothelial carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Radiology Nuclear Medicine and imaging

Cite this

Preoperative hydronephrosis : Independent predictor for changes in renal function following nephroureterectomy. / Hoshino, Katsura; Kikuchi, Eiji; Tanaka, Nobuyuki; Akita, Hirotaka; Ito, Yujiro; Miyajima, Akira; Jinzaki, Masahiro; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 42, No. 3, hyr199, 03.2012, p. 202-207.

Research output: Contribution to journalArticle

@article{9e893ada97594540ab34fb9e10772610,
title = "Preoperative hydronephrosis: Independent predictor for changes in renal function following nephroureterectomy",
abstract = "Objective: Partial or complete urinary obstruction caused by a tumor itself may affect renal function and the eligibility for perioperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma. We investigated whether the status of preoperative hydronephrosis provides additional predictive information concerning changes in perioperative renal function. Methods: A total of 155 patients who underwent nephroureterectomy for upper tract urothelial carcinoma from 1997 to 2010 were identified. The association between preoperative parameters including the grade of hydronephrosis and perioperative renal function was analyzed. Results: Hydronephrosis was observed in 104 patients. The grade of hydronephrosis was 1, 2, 3 and 4 in 6 (3.9{\%}), 25 (16.1{\%}), 42 (27.1{\%}) and 31 (20.0{\%}) cases. Using a defined cut-off creatinine clearance value of ≥50 ml/min indicating eligibility for cisplatin-based chemotherapy, only 94 patients (60.6{\%}) were eligible in the neoadjuvant setting. Of these 94 patients, 30 (31.9{\%}) were judged to be ineligible in the adjuvant setting. Multivariate analysis demonstrated that patient age ≥70 years [P < 0.001, hazard ratio (HR) 27.9] and the absence of a higher grade hydronephrosis (P = 0.013, HR 7.40) were independent risk factors for predicting patients ineligible to receive adjuvant cisplatin-based chemotherapy. The proportion of patients ineligible to receive cisplatin-based chemotherapy changed from 40.9 to 88.6{\%} following nephroureterectomy in patients aged ≥70 years and those with no or a lower grade hydronephrosis. Conclusions: The status of hydronephrosis is an independent predictor of eligibility to receive adjuvant cisplatin-based chemotherapy. The information on preoperative hydronephrosis and patient age may assist in part of the decision-making when considering neoadjuvant cisplatin-based chemotherapy.",
keywords = "Age, Hydronephrosis, Nephroureterectomy, Renal function, Upper tract urothelial carcinoma",
author = "Katsura Hoshino and Eiji Kikuchi and Nobuyuki Tanaka and Hirotaka Akita and Yujiro Ito and Akira Miyajima and Masahiro Jinzaki and Mototsugu Oya",
year = "2012",
month = "3",
doi = "10.1093/jjco/hyr199",
language = "English",
volume = "42",
pages = "202--207",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Preoperative hydronephrosis

T2 - Independent predictor for changes in renal function following nephroureterectomy

AU - Hoshino, Katsura

AU - Kikuchi, Eiji

AU - Tanaka, Nobuyuki

AU - Akita, Hirotaka

AU - Ito, Yujiro

AU - Miyajima, Akira

AU - Jinzaki, Masahiro

AU - Oya, Mototsugu

PY - 2012/3

Y1 - 2012/3

N2 - Objective: Partial or complete urinary obstruction caused by a tumor itself may affect renal function and the eligibility for perioperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma. We investigated whether the status of preoperative hydronephrosis provides additional predictive information concerning changes in perioperative renal function. Methods: A total of 155 patients who underwent nephroureterectomy for upper tract urothelial carcinoma from 1997 to 2010 were identified. The association between preoperative parameters including the grade of hydronephrosis and perioperative renal function was analyzed. Results: Hydronephrosis was observed in 104 patients. The grade of hydronephrosis was 1, 2, 3 and 4 in 6 (3.9%), 25 (16.1%), 42 (27.1%) and 31 (20.0%) cases. Using a defined cut-off creatinine clearance value of ≥50 ml/min indicating eligibility for cisplatin-based chemotherapy, only 94 patients (60.6%) were eligible in the neoadjuvant setting. Of these 94 patients, 30 (31.9%) were judged to be ineligible in the adjuvant setting. Multivariate analysis demonstrated that patient age ≥70 years [P < 0.001, hazard ratio (HR) 27.9] and the absence of a higher grade hydronephrosis (P = 0.013, HR 7.40) were independent risk factors for predicting patients ineligible to receive adjuvant cisplatin-based chemotherapy. The proportion of patients ineligible to receive cisplatin-based chemotherapy changed from 40.9 to 88.6% following nephroureterectomy in patients aged ≥70 years and those with no or a lower grade hydronephrosis. Conclusions: The status of hydronephrosis is an independent predictor of eligibility to receive adjuvant cisplatin-based chemotherapy. The information on preoperative hydronephrosis and patient age may assist in part of the decision-making when considering neoadjuvant cisplatin-based chemotherapy.

AB - Objective: Partial or complete urinary obstruction caused by a tumor itself may affect renal function and the eligibility for perioperative cisplatin-based chemotherapy in patients with upper tract urothelial carcinoma. We investigated whether the status of preoperative hydronephrosis provides additional predictive information concerning changes in perioperative renal function. Methods: A total of 155 patients who underwent nephroureterectomy for upper tract urothelial carcinoma from 1997 to 2010 were identified. The association between preoperative parameters including the grade of hydronephrosis and perioperative renal function was analyzed. Results: Hydronephrosis was observed in 104 patients. The grade of hydronephrosis was 1, 2, 3 and 4 in 6 (3.9%), 25 (16.1%), 42 (27.1%) and 31 (20.0%) cases. Using a defined cut-off creatinine clearance value of ≥50 ml/min indicating eligibility for cisplatin-based chemotherapy, only 94 patients (60.6%) were eligible in the neoadjuvant setting. Of these 94 patients, 30 (31.9%) were judged to be ineligible in the adjuvant setting. Multivariate analysis demonstrated that patient age ≥70 years [P < 0.001, hazard ratio (HR) 27.9] and the absence of a higher grade hydronephrosis (P = 0.013, HR 7.40) were independent risk factors for predicting patients ineligible to receive adjuvant cisplatin-based chemotherapy. The proportion of patients ineligible to receive cisplatin-based chemotherapy changed from 40.9 to 88.6% following nephroureterectomy in patients aged ≥70 years and those with no or a lower grade hydronephrosis. Conclusions: The status of hydronephrosis is an independent predictor of eligibility to receive adjuvant cisplatin-based chemotherapy. The information on preoperative hydronephrosis and patient age may assist in part of the decision-making when considering neoadjuvant cisplatin-based chemotherapy.

KW - Age

KW - Hydronephrosis

KW - Nephroureterectomy

KW - Renal function

KW - Upper tract urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84857988178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857988178&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyr199

DO - 10.1093/jjco/hyr199

M3 - Article

C2 - 22246718

AN - SCOPUS:84857988178

VL - 42

SP - 202

EP - 207

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

M1 - hyr199

ER -